Stoke Therapeutics, Inc. Operating Lease, Weighted Average Discount Rate, Percent
Stoke Therapeutics, Inc. (STOK) had Operating Lease, Weighted Average Discount Rate, Percent of 10.05% as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent · last filed 2026-08-03
- 2026-06-30: Operating Lease, Weighted Average Discount Rate, Percent 10.05%.
- 2026-03-31: Operating Lease, Weighted Average Discount Rate, Percent 10.09%.
- 2025-12-31: Operating Lease, Weighted Average Discount Rate, Percent 10.12%.
- 2025-09-30: Operating Lease, Weighted Average Discount Rate, Percent 10.15%.
| Period end | Operating Lease, Weighted Average Discount Rate, Percent |
|---|---|
| 2026-06-30 | 10.05% 10-Q · filed 2026-08-03 |
| 2026-03-31 | 10.09% 10-Q · filed 2026-05-07 |
| 2025-12-31 | 10.12% 10-K · filed 2026-03-16 |
| 2025-09-30 | 10.15% 10-Q · filed 2025-11-04 |
| 2025-06-30 | 10.25% 10-Q · filed 2025-08-12 |
| 2025-03-31 | 10.25% 10-Q · filed 2025-05-13 |
| 2024-12-31 | 10.21% 10-K · filed 2025-03-18 |
| 2024-09-30 | 10.11% 10-Q · filed 2024-11-05 |
| 2024-06-30 | 10.03% 10-Q · filed 2024-08-07 |
| 2024-03-31 | 9.97% 10-Q · filed 2024-05-06 |
| 2023-12-31 | 9.92% 10-K · filed 2024-03-25 |
| 2023-09-30 | 4.70% 10-Q · filed 2023-11-07 |
| 2023-06-30 | 4.70% 10-Q · filed 2023-08-07 |
| 2023-03-31 | 4.69% 10-Q · filed 2023-05-04 |
| 2022-12-31 | 4.69% 10-K · filed 2023-03-06 |
| 2022-09-30 | 4.69% 10-Q · filed 2022-11-14 |
| 2022-06-30 | 4.65% 10-Q · filed 2022-08-08 |
| 2022-03-31 | 4.15% 10-Q · filed 2022-05-10 |
| 2021-12-31 | 4.14% 10-K · filed 2022-03-10 |
| 2021-09-30 | 4.14% 10-Q · filed 2021-11-08 |
| 2021-06-30 | 5.74% 10-Q · filed 2021-08-10 |
| 2021-03-31 | 7.01% 10-Q · filed 2021-05-10 |
| 2020-12-31 | 7.02% 10-K · filed 2021-03-09 |
| 2020-09-30 | 7.02% 10-Q · filed 2020-11-12 |
| 2020-06-30 | 7.03% 10-Q · filed 2020-08-10 |
| 2020-03-31 | 7.03% 10-Q · filed 2020-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |